New York Mets second baseman Robinson Cano has been suspended for the 2021 season after testing positive for a performance enhancing drug.

It’s Cano’s second career PED suspension, and the first was in 2018 where he was suspended for 80 games with the Mariners.

Cano tested positive for Stanozolol, an anabolic steroid derived from dihydrotestosterone.

The suspension means Cano will forfeit $24 million in salary for the upcoming season.

Although he’ll miss 2021, Cano will still be owed $48 million over 2022 and 2023 under his current contract.